Alizé Pharma is a company member of Lyonbiopole, specialized in the development of biopharmaceuticals for the treatment of metabolic disorders and rare diseases. Alizé just would acquire exclusive worldwide rights to a novel peptide targeting bone diseases. A new company, Alizé Pharma SAS III, was created to develop this project. Alizé also announced this month the positive results of two Phase I clinical trials AZP -531, a ghrelin analogue unacylated, in 76 subjects including healthy volunteers and patients are overweight or obese.
ABOUT ALIZÉ PHARMA
Alizé Pharma is a group of companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The management is a team of drug development experts and the board of directors has a breadth of international experience. Its business strategy is to advance programs based on medical innovation to the clinical stage and establish partnerships with pharmaceutical companies to secure both short and long-term revenue streams. Since its creation in 2007 the group has raised €13.3 million ($16.6 million) from private and institutional investors. It has advanced two programs to the clinical phase and has also signed its first industrial partnership.
The first group entity, Alizé Pharma SAS, is working on a peptide derived from unacylated ghrelin (AZP-531). This program is in Phase II clinical development for the treatment of Prader-Willi syndrome and in Phase Ib for type 2 diabetes. The second entity, Alizé Pharma II SAS, is focusing on the development of pegcrisantaspase (ASPAREC® / JZP416), a new pegylated recombinant Lasparaginase for the treatment of acute lymphoblastic leukemia (ALL). It is partnered with Jazz Pharmaceuticals (Nasdaq: JAZZ) and is currently in Phase II/III clinical development.
Founded in 2014, Alizé Pharma III SAS has acquired exclusive worldwide rights to develop and commercialize a family of new peptides with bone anabolic properties.